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Abstract
Background: Health care-associated infections (HAI) have been shown to increase length of stay, the cost of care,
and rates of hospital deaths (Kaye and Marchaim, J Am Geriatr Soc 62(2):306–11, 2014; Roberts and Scott, Med Care
48(11):1026–35, 2010; Warren and Quadir, Crit Care Med 34(8):2084–9, 2006; Zimlichman and Henderson, JAMA
Intern Med 173(22):2039–46, 2013). Importantly, infections acquired during a hospital stay have been shown to be
preventable (Loveday and Wilson, J Hosp Infect 86:S1–70, 2014). In particular, due to more invasive procedures,
mechanical ventilation, and critical illness, patients cared for in the intensive care unit (ICU) are at greater risk of HAI
and associated poor outcomes. This meta-analysis aims to summarise the effectiveness of chlorhexidine (CHG)
bathing, in adult intensive care patients, to reduce infection.
Methods: A systematic literature search was undertaken to identify trials assessing the effectiveness of CHG bathing to
reduce risk of infection, among adult intensive care patients. Infections included were: bloodstream infections; central
line-associated bloodstream infections (CLABSI); catheter-associated urinary tract infections; ventilator-associated
pneumonia; methicillin-resistant Staphylococcus aureus (MRSA); vancomycin-resistant Enterococcus; and Clostridium
difficile. Summary estimates were calculated as incidence rate ratios (IRRs) and 95% confidence/credible intervals.
Variation in study designs was addressed using hierarchical Bayesian random-effects models.
Results: Seventeen trials were included in our final analysis: seven of the studies were cluster-randomised crossover
trials, and the remaining studies were before-and-after trials. CHG bathing was estimated to reduce the risk of CLABSI by
56% (Bayesian random effects IRR = 0.44 (95% credible interval (CrI), 0.26, 0.75)), and MRSA colonisation and bacteraemia
in the ICU by 41% and 36%, respectively (IRR = 0.59 (95% CrI, 0.36, 0.94); and IRR = 0.64 (95% CrI, 0.43, 0.91)). The numbers
needed to treat for these specific ICU infections ranged from 360 (CLABSI) to 2780 (MRSA bacteraemia).
Conclusion: This meta-analysis of the effectiveness of CHG bathing to reduce infections among adults in the ICU
has found evidence for the benefit of daily bathing with CHG to reduce CLABSI and MRSA infections. However, the
effectiveness may be dependent on the underlying baseline risk of these events among the given ICU population.
Therefore, CHG bathing appears to be of the most clinical benefit when infection rates are high for a given
ICU population.
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Background
Health care-associated infections (HAI) have been
shown to increase length of hospital stay, the cost of
care, and rates of hospital deaths [1–4]. Importantly, in-
fections acquired during a hospital stay have been shown
to be preventable [5]. Patients cared for in the ICU are
at increased risk of HAI due to the invasive nature of
many treatments such as mechanical ventilation, urinary
catheterisation, and central venous access. Efforts
have been made to reduce hospital-acquired infections
among adult intensive care patients, including increased
hand hygiene, bundles for insertion of vascular access
devices, the screening and isolation of patients colo-
nised with multidrug-resistant organisms, and decon-
taminating the skin with chlorhexidine (CHG) [6, 7].
The skin of patients is considered a major reservoir
for pathogens associated with hospital-acquired infec-
tions [8], and has been suggested as a potential target
for interventions to reduce bacterial burden and subse-
quent risk of infection. The use of daily CHG bathing in
intensive care patients has been advocated to reduce
many of the infections in critically ill patients [9]. How-
ever, the effectiveness of CHG bathing to reduce ICU in-
fections has varied considerably among published trials,
making the effectiveness of CHG bathing in ICU pa-
tients uncertain [10]. This variability has been suggested
to be associated with the underlying risk of infection among
the ICU patients included in the various trials, with the
greatest benefit observed among patients with the highest
prevalence of infection at baseline [10]. This meta-analysis
was therefore undertaken to summarise the effectiveness of
CHG bathing among adult intensive care patients in
reducing various infections in the ICU, namely: blood-
stream infections (BSI); central line-associated bloodstream
infections (CLABSI); catheter-associated urinary tract
infections (CAUTI); ventilator-associated pneumonia
(VAP); methicillin-resistant Staphylococcus aureus (MRSA);
vancomycin-resistant Enterococcus (VRE); and Clostridium
difficile (C-diff).
Methods
This meta-analysis was planned, undertaken, and reported
using the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guidelines [11].
Data sources and search strategy
A systematic literature search was undertaken of medical
literature databases including MEDLINE, EMBASE, and
Cochrane Library published up until March 2016.
Keywords and title searches included a combination of:
“Chlorhexidine”, “bath$”, “intensive care”, “prevention”,
“infection$”, and “effectiveness”. Hand searching of the
references of research papers was also undertaken until
no new studies were identified.
Study selection
Inclusion and exclusion criteria
The eligibility for inclusion of research papers into in
this meta-analysis was considered independently by two
authors (SAF and M-CA). Only trials of the effectiveness
to reduce infections in adult ICU patients were included.
Review papers, non-adult populations, non-ICUs, and
papers that did not report the rates per ICU-days at risk
were excluded.
Data extraction and synthesis
Data extracted from each paper included: first authors’
names and publication year, country of study, duration of
study, study site, study design (RCT, before and after) type
of ICU setting (surgical, medical, mixed, etc.), infection of
interest, and number of events and ICU-days at risk.
Statistical methods
Individual study and combined estimates of the effect-
iveness of CHG bathing to prevent infections (incidence
rate ratios (IRRs)) are presented as forest plots [12]. Het-
erogeneity of effectiveness between studies was assessed
using an I2 statistic and p < 0.1 was chosen as evidence
of statistical heterogeneity. Initial analysis identified the
presence of statistical heterogeneity, and therefore sum-
mary estimates for fixed effects and random effects (RE)
models are presented [13].
Because of the inclusion of both before-and-after and
randomised-cluster crossover trials, summary estimates
are also presented using the method suggested by Sutton
and Abrams [14]. This approach uses a three-level hier-
archical model of the heterogeneity between-study de-
sign types, in addition to the heterogeneity between
individual studies. Contrasting with traditional approaches,
Bayesian methods do not use p values to assess statis-
tical significance; in a similar manner to the use of confi-
dence intervals (CIs), credible intervals (CrIs) are used
to identify the significance of results. For instance, an es-
timate of effect as a ratio (i.e. a relative risk) with a 95%
CrI that does not include the null (1.0) is considered
statistically significant. To assess the potential role of
baseline risk for the observed heterogeneity between
individual studies, a Bayesian meta-regression approach
was also used [15].
In this approach, any regression estimates exhibiting a
negative relationship between baseline risk and treat-
ment effect are showing that treatment benefit increased
when baseline risk of infection was higher among the
given ICU population. Traditional meta-analysis models
were developed using the R metafor and meta packages
[16]. Bayesian models used non-informative priors
with the R2Winbugs package from R, and WinBUGS
software [17–19]. Also, because of the inclusion of both
before-and-after and randomised studies in our meta-
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analysis, final interpretation of the effectiveness of CHG
bathing was based on Bayesian models. Assessment of
publication bias was assessed by inspection of funnel
plots and a test of plot asymmetry using a weighted lin-
ear regression method [20].
Results
Search results
The electronic search resulted in 114 potential papers to
be included. Following review of the abstract, or the
complete paper when required, 17 before-and-after or
randomised-cluster crossover trials were included in our
analysis. Reasons why papers were excluded from our
final analysis were due to being them being review pa-
pers, not among adult ICU patients, and trials that in-
cluded multiple interventions. Characteristics of the 17
studies are presented in Additional file 1: Table S1.
Seven of the studies used a cluster-randomised crossover
design, and the remaining studies were of a before-and-
after design (the study by Huang et al. [21] reports both
before-and-after and randomised-cluster results).
Summary estimates of the effectiveness CHG bathing
to reduce infections among adult ICU patients are
presented in Table 1, and in the forest plot figures
(Additional file 2).
Bloodstream infections
Daily bathing with CHG was estimated to reduce BSI in
the ICU by approximately 20% (Bayesian RE-IRR = 0.79,
95% CrI 0.60, 1.03). Summary estimates for specific
study designs were IRR = 0.86 (95% CI 0.41, 1.83) and
IRR = 0.79 (95% CI 0.64, 0.97) for before-and-after and
RCT studies respectively. Meta-regression of the
relationship between risk among the control group and
effectiveness of CHG bathing (Table 1), slope = –0.125
(95% CrI –0.180, –0.071).
Catheter-related bloodstream infections
Daily bathing with CHG was estimated to reduce CLABSI
in the ICU by approximately 56% (Bayesian RE-IRR = 0.44,
95% CrI 0.26, 0.75). Summary estimates for specific study
designs were IRR = 0.47 (95% CrI 0.32, 0.70) and IRR =
0.50 (95% CrI 0.31, 0.81) for before-and-after and RCT
studies respectively. From meta-regression of the relation-
ship between risk among control group and effectiveness
of CHG bathing (Table 1), slope =–0.050 (95% CrI –0.123,
0.023).
Ventilator-associated pneumonia
Daily bathing with CHG was estimated to reduce VAP in
the ICU by approximately 18% (Bayesian RE-IRR = 0.82,
95% CrI 0.57, 1.25). Summary estimates for specific
study designs were IRR = 0.77 (95% CrI 0.63, 0.95) and
IRR = 1.19 (95% CrI 0.66, 2.13) for before-and-after and
RCT studies respectively. From meta-regression of the
relationship between risk among control group and ef-
fectiveness of CHG bathing (Table 1), slope = –0.026
(95% CrI –0.055, 0.002).
Catheter-related urinary tract infections
Daily bathing with CHG was estimated to reduce CAUTI
in the ICU by approximately 7% (Bayesian RE-IRR = 0.93,
95% CrI 0.45, 1.66). Summary estimates for specific study
designs were IRR = 0.98 (95% CrI 0.71, 1.35) and IRR = 0.89
(95% CI 0.57, 1.41) for before-and-after and RCT studies re-
spectively. From meta-regression of the relationship
Table 1 Fixed effects, random effects, Bayesian random effects, and meta-regression estimates of the effectiveness of
chlorhexidine bathing
Summary estimate IRR (95% CI/CrI) Meta-regression
Outcome Fixed effects (I) Random effects (DL) Bayesian (RE) Slope (95% CrI)
BSI 0.79 (0.73, 0.86)a 0.79 (0.60, 1.03) 0.78 (0.45, 1.23) –0.125 (–0.180, –0.071)a
CLABSI 0.64 (0.56, 0.74)a 0.49 (0.35, 0.68)a 0.44 (0.26, 0.75)a –0.050 (–0.123, 0.0231)
VAP 0.83 (0.71, 0.98)a 0.85 (0.67, 1.07) 0.82 (0.57, 1.25) –0.026 (–0.055, 0.002)
CAUTI 1.04 (0.91, 1.18) 0.98 (0.79, 1.21) 0.93 (0.45, 1.66) –0.008 (–0.048, 0.032)
MRSA-C 0.59 (0.53, 0.65)a 0.58 (0.47, 0.71)a 0.59 (0.36, 0.94)a –0.010 (–0.0154, 0.005)
MRSA-B 0.66 (0.52, 0.84)a 0.66 (0.52, 0.84)a 0.64 (0.43, 0.91)a –0.155 (–0.364, 0.054)
VRE-C 0.58 (0.47, 0.73)a 0.52 (0.33, 0.82)a 0.53 (0.20, 1.55) –0.027 (–0.065, 0.010)
VRE-B 0.45 (0.25, 0.82)a 0.63 (0.19, 2.08) 0.53 (0.15, 2.26) –1.006 (–1.830, –0.182)a
C-diff 1.04 (0.91, 1.18) 0.98 (0.48, 1.80) 0.93 (0.48, 1.80) 0.008 (–0.048, 0.032)
aEstimates with 95% CrI excluding the null (0 for regression, and 1 for IRR)
IRR incidence rate ratio, I inverse variance, DL DerSimonian-Laird, RE random effects, CI confidence interval from Bayesian models, CrI credible interval from Bayesian
models, BSI bloodstream infection, CAUTI catheter-associated urinary tract infections, C-diff Clostridium Difficile, CLABSI central line-associated bloodstream infection,
MRSA methicillin-resistant Staphylococcus aureus, MRSA-C MRSA colonisation, MRSA-B MRSA-associated BSI, VAP ventilator-associated pneumonia, VRE vancomycin-
resistant Enterococcus, VRE-C VRE colonisation, VRE-B VRE-associated BSI
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between risk among control group and effectiveness of
CHG bathing (Table 2), slope =–0.008 (95% CrI –0.048,
0.032).
Methicillin-resistant Staphylococcus aureus
Daily bathing with CHG was estimated to reduce MRSA
colonisation and bacteraemia in the ICU by approxi-
mately 41% and 36%, respectively (MRSA-C Bayesian
RE-IRR = 0.59, 95% CrI 0.36, 0.94; and MRSA-B Bayesian
RE-IRR = 0.64, 95% CrI 0.43, 0.91). For MRSA colonisa-
tion, summary estimates for specific study designs were
IRR = 0.52 (95% CrI 0.39, 0.68) and IRR = 0.68 (95% CrI
0.58, 0.80) for before-and-after and RCT studies respect-
ively. From meta-regression of the relationship between
risk among control group and effectiveness of CHG
bathing to prevent MRSA colonisation (Table 1),
slope = –0.010 (95% CrI –0.005, 0.015). For MRSA bacter-
aemia, summary estimates for specific study designs were
Bayesian RE-IRR = 0.68 (95% CrI 0.48, 0.96) and Bayesian
RE-IRR = 0.64 (95% CrI 0.44, 0.94) for before-and-after
and RCT studies respectively. From meta-regression of
the relationship between risk among control group and ef-
fectiveness of CHG bathing to prevent MRSA bacteraemia
(Table 1), slope = –0.155 (95% CrI –0.364, 0.054).
Vancomycin-resistant Enterococcus
Daily bathing with CHG was estimated to reduce both
VRE colonisation and bacteraemia in the ICU by approxi-
mately 37% (VRE-C Bayesian RE-IRR = 0.53, 95% CrI
0.20, 1.55; and VRE-B Bayesian RE-IRR = 0.53, 95% CrI
0.15, 2.26). From meta-regression of the relationship be-
tween risk among control group and effectiveness of CHG
bathing to prevent VRE colonisation (Table 1), slope = –
0.027 (95% CrI –0.065, 0.010). For VRE bacteraemia, from
meta-regression of the relationship between risk among
control group and effectiveness of CHG bathing (Table 1),
slope = –1.01 (95% CrI –1.830, –0.182).
Clostridium difficile
Daily bathing with CHG was estimated to reduce C-diff
infection in the ICU by approximately 7% (Bayesian
RE-IRR = 0.93, 95% CrI 0.48, 1.80). Summary estimates
for specific study designs were IRR = 0.0.98 (95% CrI 0.71,
1.35) and IRR = 0.89 (95% CrI 0.57, 1.41) for before-and-
after and RCT studies respectively. From meta-regression
of the relationship between risk among control group and
effectiveness of CHG bathing (Table 1), slope = 0.008 (95%
CrI –0.048, 0.032).
Publication bias
Inspection of funnel plots and the results of tests of
symmetry of included trials suggested no evidence for
publication bias.
Absolute risk reduction and numbers needed to treat
Relative risk, median baseline risk during control periods,
risk with treatment, absolute risk reduction, and number
needed to treat (NNT) to prevent a single event are pre-
sented in Table 2. Median baseline risk (during control
periods) ranged from 1/1000 days to 10/1000 days for the
various outcomes of interest. The lowest baseline risk was
observed among bacteraemia associated with MRSA or
VRE (<1 case/1000 days at risk in the ICU), and the high-
est baseline risk was observed for VAP (median 10/1000
ventilation-days). The lowest NNT was estimated for
CHG bathing to prevent CLABSI and VRE colonisation
among ICU patients (NNT = 360 and 425, respectively).
The highest estimated NNT was for CHG bathing to pre-
vent MRSA bacteraemia and C-diff among ICU patients
(NNT = 2780 and 14,290, respectively).
Table 2 Relative risk, baseline risk, risk with treatment, absolute risk reduction, and number needed to treat
Outcome Relative effect (95% CrI) Median (IQR) baseline
risk per 1000 days
Risk difference per 1000 days
(95% CrI)
Number needed to treat
BSI 0.78 (0.45, 1.03) 5 (4–6) 1.1 (3 fewer to 0.1 more) 910
CLABSI 0.44 (0.26, 0.75)a 5 (3–9) 2.8 (4 fewer to 1.2 fewer)a 360
VAP 0.82 (0.57, 1.25) 10 (5–16) 1.8 (4 fewer to 3 more) 560
CAUTI 0.93 (0.45, 1.66) 8 (2–14) 0.56 (5 fewer to 5 more) 1565
MRSA-C 0.59 (0.36, 0.94)a 4 (3–22) 1.64 (3 fewer to 0.2 fewer)a 595
MRSA-B 0.64 (0.43, 0.91)a 1 (0.2–2) 0.36 (0.6 fewer to 0.1 fewer)a 2780
VRE-C 0.53 (0.20, 1.55) 5 (4–15) 2.35 (4 fewer to 3 more) 425
VRE-B 0.53 (0.15, 2.26) 1 (0.5–2) 0.47 (0.9 fewer to 1.3 more) 2130
C-diff 0.93 (0.48, 1.80) 1 (0.5–3) 0.07 (0.5 fewer to 0.8 more) 14,290
aEstimates with 95% CrI excluding the null (1 for IRR)
IRR incidence rate ratio, CrI credible interval from Bayesian models, BSI bloodstream infection, CAUTI catheter-associated urinary tract infections, C-diff Clostridium
Difficile, CLABSI central line-associated bloodstream infection, MRSA methicillin-resistant Staphylococcus aureus, MRSA-C MRSA colonisation, MRSA-B MRSA-associated BSI,
VAP ventilator-associated pneumonia, VRE vancomycin-resistant Enterococcus, VRE-C VRE colonisation, VRE-B VRE-associated BSI
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Discussion
This meta-analysis presents a summary of the estimated
benefit of CHG bathing to prevent infection in the ICU.
CHG bathing was most effective for the prevention of
CLABSI among ICU patients, demonstrating a 56% re-
duction. However, the magnitude of benefit is affected
by the underlying risk of CLABSI among ICU popula-
tions. Even among an average risk group of five CLABSI
per 1000 central-line-days, 360 patients will need to be
bathed with CHG to prevent a single event. If the under-
lying risk of CLABSI is only 1 per 1000 central-line-days
than the NNT increases to 1780. Effectiveness was also
shown for reducing MRSA colonisation and MRSA bac-
teraemia. However, even among average baseline-risk
populations, the NNT is approximately 600 and 2800,
respectively. Because of varying study designs (before-
and-after versus randomised crossover trials), there
remains uncertainty in the effectiveness of CHG-B to
prevent other infections among adults in the ICU.
Previous reviews of daily CHG bathing to reduce in-
fections in the ICU have been undertaken [22–24], and
confirm an observed benefit in CHG bathing to reduce
CLABSI and MRSA infection in the ICU. There was
considerable variation in the baseline risk of infection in
the ICU populations included in the included previous
reviews. However, there was no attempt to account for
the variability due to study design (the heterogeneity be-
tween before-and-after compared with the randomised-
cluster trials in some cases differed fourfold).
A potential strength of our meta-analysis is the inclu-
sion of a wide range of infections associated with an ICU
stay. In particular, we have attempted to account for the
uncertainty of average estimates by using a Bayesian ap-
proach to account for variation due to study design. We
have also presented the potential clinical effectiveness of
CHG bathing for various ICU infections by estimating the
absolute rates of infection with treatment and therefore
the absolute risk reduction and NNT.
Any systematic review and meta-analysis has a poten-
tial weakness of missing unpublished trials, and potential
individual trial heterogeneity that is difficult to account
for in analysis. It is obvious from the published trials
that before-and-after trials tend to overestimate effect-
iveness, and even variation in the length of a randomised
trial may affect the ability to detect underlying benefit.
The study by Huang et al. [21] reports both before-and-
after results and cluster-randomised results for BSI; the
estimate of effect is greater for the before-and-after de-
sign, when compared with the cluster grouped outco-
mes—confirming the potential overestimation of the
effectiveness of CHG bathing when compared with his-
torical control periods.
The length of the study intervention and the control
period have been proposed to suggest the difference
between the results obtained by Climo et al. [25] and Noto
et al. [26]: in the latter CHG bathing was found to be
ineffective, while the former trial (with 6-month interven-
tion period) found CHG bathing effective in reducing
multidrug-resistant infections. An intervention period of
only 10-weeks, compared to a 10-week control period,
used in the study by Noto et al. [26] has been suggested to
be insufficient to determine the true impact of CHG bath-
ing on infection rates among adult ICU patients. However,
any potential benefit of an intervention must be assessed
in relation to the absolute effectiveness among specific
populations of patients, taking into account baseline risk.
Another potential limitation of our meta-analysis is in-
clusion of the study by Huang et al. [21], in which a
screening and isolation group (control) was compared
with a group universally decolonised using CHG bathing
and twice-daily nasal mupirocin. The removal of this
study from our analysis does not change our conclusion
for the effect of CHG bathing on CLABSI; however, re-
sults for MRSA bacteraemia or colonisation become
non-significant. Exclusion of this study assumes a signifi-
cant added effect of mupirocin, and should be consid-
ered when interpreting our final conclusions.
The results of our meta-analysis have some important
clinical implications. Each ICU must assess the potential
benefit of instituting daily CHG bathing to reduce infec-
tions in the ICU such as CLABSI and MRSA. For in-
stance, in an ICU with specific bundles to prevent
CLABSI, such as those developed by Pronovost [7, 27],
baseline rates of CLABSI may be fewer than 1 per 1000
central-line-days, and the NNT in the order of 1800 pa-
tients being bathed daily with CHG to prevent one case
of CLABSI. Any benefit from the widespread use of
CHG bathing in the ICU should consider the prevalence
of central line catheters in a given ICU setting. Also, in
terms of other types of infection in the ICU such a
C-diff, UTIs and VAP, many studies included these as sec-
ondary outcomes, and may have lacked adequate sample
sizes to assess a lesser effectiveness of CHG bathing.
There are concerns regarding the use of daily bathing
of ICU patients with CHG. Although CHG bathing aims
to reduce HAI, it may promote the emergence of CHG
resistance, and increase Gram-negative organism bacter-
aemia [10]. However, even modest treatment effects
should be considered in the context of the seriousness of
some of these specific infections among ICU patients.
Conclusion
Our meta-analysis of the effectiveness of CHG bathing
to reduce infections among adults in the ICU has found
evidence for the benefit of daily bathing with CHG to re-
duce CLABSI and MRSA infections in the ICU. How-
ever, the effectiveness was dependent on the underlying
risk of these events in the given ICU.
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Additional files
Additional file 1: Table S1. Presenting a summary of study
characteristics of the 17 trials on daily CHG bathing of ICU patients.
(DOCX 35 kb)
Additional file 2: Forest plots presenting the effectiveness of CHG
bathing in reducing: BSI (panel A), CLABSI (panel B), VAP (panel C), CAUTI
(panel D), MRSA colonisation (panel E), MRSA associated BSI (panel F), VRE
colonisation (panel G), VRE associated BSI (panel H), and Clostridium Difficile
infections (panel I). FE = fixed effects, RE = random effects. (PDF 0.98 mb)
Abbreviations
BSI: Bloodstream infection; CAUTI: Catheter-associated urinary tract infections;
C-Diff: Clostridium difficile; CHG: Chlorhexidine gluconate; CI: Confidence
interval; CLABSI: Central line-associated bloodstream infection; CrI: Credible
interval; HAI: Health care-associated infection; ICU: Intensive care unit;
IRR: Incidence rate ratio; MRSA: Methicillin-resistant Staphylococcus aureus;
NNT: Number needed to treat; RE: Random effects; VAP: Ventilator-associated
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